WallStreetZenWallStreetZen

NASDAQ: ABOS
Acumen Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for ABOS

Based on 1 analyst offering 12 month price targets for Acumen Pharmaceuticals Inc.
Min Forecast
$15.00+455.56%
Avg Forecast
$15.00+455.56%
Max Forecast
$15.00+455.56%

Should I buy or sell ABOS stock?

Based on 1 analyst offering ratings for Acumen Pharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ABOS stock forecasts and price targets.

ABOS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-15

1 of 1

Forecast return on equity

Is ABOS forecast to generate an efficient return?
Company
-32.56%
Industry
76.1%
Market
79%
ABOS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ABOS forecast to generate an efficient return on assets?
Company
-28.35%
Industry
30.96%
ABOS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ABOS earnings per share forecast

What is ABOS's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$1.06
Avg 2 year Forecast
-$1.37
Avg 3 year Forecast
-$1.31

ABOS revenue forecast

What is ABOS's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$26.5M
Avg 2 year Forecast
$56.2M
Avg 3 year Forecast
$120.8M

ABOS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ABOS$2.70$15.00+455.56%Buy
DRTS$2.33$8.00+243.35%Strong Buy
IVA$3.10$22.33+620.42%Strong Buy
ZURA$3.74$23.50+528.34%Strong Buy
TELO$5.51N/AN/A

Acumen Pharmaceuticals Stock Forecast FAQ

Is Acumen Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ABOS) stock is to Buy ABOS stock.

Out of 1 analyst, 0 (0%) are recommending ABOS as a Strong Buy, 1 (100%) are recommending ABOS as a Buy, 0 (0%) are recommending ABOS as a Hold, 0 (0%) are recommending ABOS as a Sell, and 0 (0%) are recommending ABOS as a Strong Sell.

If you're new to stock investing, here's how to buy Acumen Pharmaceuticals stock.

What is ABOS's earnings growth forecast for 2024-2026?

(NASDAQ: ABOS) Acumen Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.61%.

Acumen Pharmaceuticals's earnings in 2024 is -$55,937,000.On average, 4 Wall Street analysts forecast ABOS's earnings for 2024 to be -$63,834,764, with the lowest ABOS earnings forecast at -$79,906,105, and the highest ABOS earnings forecast at -$52,269,407. On average, 3 Wall Street analysts forecast ABOS's earnings for 2025 to be -$82,111,033, with the lowest ABOS earnings forecast at -$111,748,387, and the highest ABOS earnings forecast at -$66,688,554.

In 2026, ABOS is forecast to generate -$78,704,509 in earnings, with the lowest earnings forecast at -$78,704,509 and the highest earnings forecast at -$78,704,509.

What is ABOS's revenue growth forecast for 2028-2030?

(NASDAQ: ABOS) Acumen Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.

Acumen Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ABOS's revenue for 2028 to be $1,593,916,510, with the lowest ABOS revenue forecast at $1,593,916,510, and the highest ABOS revenue forecast at $1,593,916,510. On average, 1 Wall Street analysts forecast ABOS's revenue for 2029 to be $3,375,882,726, with the lowest ABOS revenue forecast at $3,375,882,726, and the highest ABOS revenue forecast at $3,375,882,726.

In 2030, ABOS is forecast to generate $7,257,637,182 in revenue, with the lowest revenue forecast at $7,257,637,182 and the highest revenue forecast at $7,257,637,182.

What is ABOS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ABOS) forecast ROA is -28.35%, which is lower than the forecast US Biotechnology industry average of 30.96%.

What is ABOS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ABOS price target, the average ABOS price target is $15.00, with the highest ABOS stock price forecast at $15.00 and the lowest ABOS stock price forecast at $15.00.

The Wall Street analyst predicted that Acumen Pharmaceuticals's share price could reach $15.00 by May 15, 2025. The average Acumen Pharmaceuticals stock price prediction forecasts a potential upside of 455.56% from the current ABOS share price of $2.70.

What is ABOS's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: ABOS) Acumen Pharmaceuticals's current Earnings Per Share (EPS) is -$1.06. On average, analysts forecast that ABOS's EPS will be -$1.06 for 2024, with the lowest EPS forecast at -$1.33, and the highest EPS forecast at -$0.87. On average, analysts forecast that ABOS's EPS will be -$1.37 for 2025, with the lowest EPS forecast at -$1.86, and the highest EPS forecast at -$1.11. In 2026, ABOS's EPS is forecast to hit -$1.31 (min: -$1.31, max: -$1.31).

What is ABOS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ABOS) forecast ROE is -32.56%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.